Trial ID or NCT#

NCT04577300

Status

recruiting iconRECRUITING

Purpose

To determine the safety and efficacy over 24 months of dual NT-501 CNTF encapsulated cell therapy (ECT) on visual impairment related to glaucoma.

Official Title

A Randomized, Sham Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for the Treatment of Glaucoma

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Jeffrey Goldberg, MD, PhD
Jeffrey Goldberg, MD, PhD
Ophthalmologist
Blumenkranz Smead Professor

Contact us to find out if this trial is right for you.

CONTACT

Mariana Nunez
(650) 497-7846